Skip to main content
TipRanks
Go Ultimate75% OFF

NeuroPace (NPCE) Q3 2026 Earnings Report

144 Followers

NPCE Q3 2026 EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$0.11

NPCE Q3 2026 Revenue Results

Actual Revenue
$23.10M
Expected Revenue
$27.13M
Beat/Miss
Missed by -$4.02M
YoY Revenue Growth
-15.54%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
NPCE Upcoming Earnings

NeuroPace's next earnings date is estimated for March 9, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

NPCE Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-33.69%|
Earnings Call Sentiment|Neutral

The call was mixed. NeuroPace reported a disappointing third quarter, a sharp reduction in full-year revenue guidance, operational disruption in large accounts and an expected full-year adjusted EBITDA loss. However, management described the commercial issues as largely transient, cited recovery in procedure volumes and former SEEG accounts, reported improved margins and operating results, and highlighted strong clinical, regulatory and product catalysts across IGE, adolescent focal epilepsy and Remote Care. The positive pipeline and corrective actions were substantial, but they did not fully offset the current-period execution shortfall and reduced outlook.

Company Guidance

NeuroPace revised full year 2026 total revenue guidance to a range of $91 million to $92 million, including RNS revenue of $90 million to $91 million, compared with the previous range of $99.5 million to $101.5 million; it continues to expect approximately $1 million of service revenue, implying full year RNS revenue growth of 10% to 11%, fourth quarter total revenue of approximately $23 million to $24 million, and underlying RNS growth of approximately 5% year-over-year at the midpoint in the fourth quarter. Full year adjusted gross margin guidance is 83% to 83.5%, adjusted operating expenses are $85 million to $86 million, excluding approximately $10 million of stock-based compensation, including adjusted sales and marketing expense of $45 million to $46 million, adjusted research and development expense of approximately $25 million, and adjusted general and administrative expense of approximately $15 million, resulting in an adjusted EBITDA loss of $8.5 million to $9.5 million. For 2027, the company expects RNS revenue growth of approximately 10% to 15% year-over-year in the first half and 15% to 20% in the second half, resulting in full year RNS revenue guidance of approximately 15%, with an acceleration toward 20% as it exits 2027; these expectations exclude any contribution from IGE indication expansion and 0 contribution from service revenue. The company expects to submit the IGE amendment around year-end, with a potential approval by midyear 2027, AURORA enrollment completed in early 2027 with potential approval by the end of 2027 or early 2028, and Remote Care approval possible in the second quarter of 2027.

  • Improved Gross Margin and Operating ResultsThird-quarter adjusted gross margin increased to 84.8% from 82.8% a year ago, an improvement of approximately 200 basis points, driven by better labor absorption. Adjusted operating expenses declined approximately 7% to $19.2 million, adjusted income from operations improved to $0.4 million from a $1.4 million loss, adjusted net loss narrowed to $0.9 million from $2.3 million, and adjusted EBITDA improved to a $0.4 million gain from a $1.3 million loss.
  • RNS Revenue Growth and Full-Year Revenue MixThird-quarter RNS System revenue was $22.9 million, up 1.4% from $22.6 million in the prior-year period. The company expects full-year RNS revenue of approximately $90 million to $91 million, representing full-year RNS revenue growth of 10% to 11% compared with 2025.
  • Record High in Active Prescribers and Broader Account BaseNeuroPace reached a new high in active prescribers during the quarter. Management also reported that a larger portion of volume is coming from a broader group of accounts, with progress in medium-sized accounts, community centers and community referrals.
  • Recovery in Large and Former SEEG AccountsThe company reported signs of recovery in several large accounts during the fourth quarter. Former SEEG accounts were also performing better relative to the rest of the account base after the company addressed the reduced routine engagement associated with exiting the SEEG distribution business.
  • Commercial Execution Improvements UnderwayNeuroPace completed changes to sales leadership, territory roles and field clinical structure. The company said the changes improved visibility into daily field activity, pipeline status and planning, while it is adding quota-carrying sales representatives, expanding account coverage and strengthening referral development and patient pipeline tools.
  • Long-Term RNS Growth Opportunity Remains a FocusManagement reiterated its conviction in the growth potential of RNS and said underlying patient need, clinician interest and market opportunity remain substantial. Management stated that there is a path back to 20% growth over time, although reaching that level will take time.
  • 2027 RNS Growth OutlookThe company expects RNS revenue growth of approximately 10% to 15% year-over-year in the first half of 2027 and 15% to 20% in the second half, resulting in full-year RNS growth of approximately 15%. These expectations exclude any contribution from IGE indication expansion and service revenue.
  • Positive Reimbursement Change for ReplacementsCMS's final 2027 OPPS rule increases the hospital outpatient payment rate for the APC covering RNS replacement procedures by approximately 11%. Management said replacements remain a small but growing portion of the procedure mix and expects the reimbursement improvement to provide an ongoing tailwind as replacement volumes increase.
  • Progress Toward IGE Regulatory SubmissionNeuroPace completed its Submission Issue Request meeting with the FDA and expects to submit an amendment around year-end. Management said the discussion clarified the clinical evidence and specific analyses requested by the FDA, and it expects a potential approval by midyear 2027 based on a full 180-day review framework.
  • Strong NAUTILUS IGE Clinical EvidenceManagement highlighted 24-month NAUTILUS results showing a 100% median reduction in generalized tonic-clonic seizures. The company stated that RNS would be the first FDA-approved device therapy for drug-resistant IGE if approved.
  • Adolescent Focal Epilepsy Program AdvancesNeuroPace initiated enrollment in AURORA, a retrospective observational study designed to include up to 100 evaluable patients who were 12 to 17 years old when they received the RNS System for drug-resistant focal epilepsy. Enrollment is expected to be completed in early 2027, with a potential submission in 2027 and potential approval by the end of 2027 or early 2028, subject to the data and FDA review.
  • Substantial Adolescent Market Opportunity IdentifiedThe company estimates that the 12- to 17-year-old adolescent focal epilepsy population represents roughly 70,000 patients or more than $3.5 billion in opportunity after approval.
  • Remote Care Submitted Ahead of ScheduleNeuroPace submitted Remote Care to the FDA during the third quarter, ahead of its previously communicated year-end timeline. The feature is designed to allow physicians to program the RNS System through telehealth, reduce the need for certain in-person visits and improve access for patients who do not live near an epilepsy center. Approval is considered possible in the second quarter of 2027, subject to FDA review.
  • Broader Product and Technology PipelineThe company said its product strategy includes Remote Care, ECoG Assistant, additional AI-enabled tools and a next-generation platform. Management described the combination of indication expansion and continued product innovation as substantial long-term growth drivers.
  • Expense Discipline While Continuing Strategic InvestmentThe company expects full-year adjusted operating expenses of $85 million to $86 million, below its previous guidance of $90 million to $92 million. Expected adjusted sales and marketing expense is $45 million to $46 million, research and development expense is approximately $25 million, and general and administrative expense is approximately $15 million, while investment continues in commercial capabilities, IGE, adolescent indication expansion, Remote Care, the NeuroPace AI suite and the next-generation RNS platform.

NPCE Earnings History

NPCE earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 09, 20272026 (Q4)-0.18--0.08――
Nov 12, 20262026 (Q3)-0.11-0.10-0.119.09% (+0.01)
Aug 11, 20262026 (Q2)-0.22-0.18-0.2630.77% (+0.08)
May 12, 20262026 (Q1)-0.23-0.20-0.214.76% (+0.01)
Mar 03, 20262025 (Q4)-0.16-0.08-0.1855.56% (+0.10)
Nov 04, 20252025 (Q3)-0.20-0.11-0.1942.11% (+0.08)
Aug 12, 20252025 (Q2)-0.22-0.26-0.260.00% (+0.00)
May 13, 20252025 (Q1)-0.24-0.21-0.3234.38% (+0.11)
Mar 04, 20252024 (Q4)-0.22-0.18-0.2321.74% (+0.05)
Nov 12, 20242024 (Q3)-0.27-0.19-0.2832.14% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed